A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.

Matteo Perrino,Silvia Bozzarelli,Paolo Andrea Zucali,Tommaso De Pas,Matteo Simonelli,Fabio De Vincenzo,Fabio Conforti,Pasquale Persico,Chiara Miggiano,Nadia Cordua,Angela Cioffi,Simona Sala,Federica Mrakic Sposta,Laura Giordano,Armando Santoro

A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.

2018

Matteo Perrino
Silvia Bozzarelli
Paolo Andrea Zucali
Tommaso De Pas
Matteo Simonelli
Fabio De Vincenzo
Fabio Conforti
Pasquale Persico
Chiara Miggiano
Nadia Cordua
Angela Cioffi
Simona Sala
Federica Mrakic Sposta
Laura Giordano
Armando Santoro

8579Background: Angiogenesis has an important role in thymic epithelial tumours (TETs); VEGF, PDGF and PDGFRα are overexpressed in TETs, and VEGF expression and microvessel density are associated w...

Keywords:

Cancer research
Pathology
Phases of clinical research
Regorafenib
Chemotherapy
Medicine
Angiogenesis
previously treated
in patient
VEGF receptors
Platelet-derived growth factor receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations